Key facts
- Ashvattha Therapeutics’s last known valuation is $310.0M (Jan 2025).
- It has raised $217.2M across 4 recorded rounds; the latest was Later Stage VC ($60.2M) in Apr 2021.
- Notable investors include Evolution VC Partners, Tribe Capital, TEDCO, Sand Hill Angels, Social Capital — 37 tracked in total.
- Ashvattha Therapeutics has filed 7 Form Ds with the SEC since 2016, most recently Dec 2022 ($60.2M sold to 107 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 37 names
- ·Watchlist + deal alerts for Ashvattha Therapeutics
Funding rounds
4 roundsAbout Ashvattha Therapeutics
Developer of hydroxyl dendrimer therapeutics designed to meet the unmet medical needs in oncology, ophthalmology and inflammatory diseases. The company's therapeutics selectively target actively endocytosing cells such as reactive microglia and macrophages responsible for chronic inflammation and disease progression within the body, enabling medical practitioners to treat patients with improved efficacy and reduced side effects.
- Sector
- Healthcare
- HQ
- Redwood City, CA, United States
- Founded
- 2015
- Employees
- 31
- Website
- avttx.com/
- Ownership
- Privately Held (backing)
Ashvattha Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ashvattha Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ashvattha Therapeutics in its N-PORT filings yet. We sweep new filings monthly.